Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Adult
Aged
Antiviral Agents
/ therapeutic use
COVID-19
/ complications
Cough
/ complications
Dementia
/ complications
Drug Combinations
Dyspnea
/ complications
Fatigue Syndrome, Chronic
/ complications
Female
Fever
/ complications
Humans
Hydroxychloroquine
/ therapeutic use
Lopinavir
/ therapeutic use
Male
Middle Aged
Oseltamivir
/ therapeutic use
Research Design
Ritonavir
/ therapeutic use
SARS-CoV-2
/ drug effects
Severity of Illness Index
Stress Disorders, Post-Traumatic
/ complications
Surveys and Questionnaires
Survivors
/ psychology
COVID-19 Drug Treatment
COVID-19
Chronic fatigue syndrome / myalgic encephalomyelitis
Post-COVID morbidities
Post-traumatic stress disorder
Journal
Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
20
10
2020
accepted:
14
01
2021
revised:
18
12
2020
pubmed:
3
2
2021
medline:
13
3
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
As the SARS-COV-2 becomes a global pandemic, many researchers have a concern about the long COVID-19 complications. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a persistent, debilitating, and unexplained fatigue disorder. We investigated psychological morbidities such as CFS and post-traumatic stress disorder (PTSD) among survivors of COVID-19 over 6 months. All COVID-19 survivors from the university-affiliated hospital of Tehran, Iran, were assessed 6 months after infection onset by a previously validated questionnaire based on the Fukuda guidelines for CFS/EM and DSM-5 Checklist for PTSD (The Post-traumatic Stress Disorder Checklist for DSM-5 or PCL-5) to determine the presence of stress disorder and chronic fatigue problems. A total of 120 patients were enrolled. The prevalence rate of fatigue symptoms was 17.5%. Twelve (10%) screened positive for chronic idiopathic fatigue (CIF), 6 (5%) for CFS-like with insufficient fatigue syndrome (CFSWIFS), and 3 (2.5%) for CFS. The mean total scores in PCL-5 were 9.27 ± 10.76 (range:0-44), and the prevalence rate of PTSD was 5.8%. There was no significant association after adjusting between CFS and PTSD, gender, comorbidities, and chloroquine phosphate administration. The obtained data revealed the prevalence of CFS among patients with COVID-19, which is almost similar to CFS prevalence in the general population. Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS. Our study suggested that medical institutions should pay attention to the psychological consequences of the COVID-19 outbreak.
Identifiants
pubmed: 33528827
doi: 10.1007/s13365-021-00949-1
pii: 10.1007/s13365-021-00949-1
pmc: PMC7852482
doi:
Substances chimiques
Antiviral Agents
0
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Oseltamivir
20O93L6F9H
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-159Références
Arch Intern Med. 2007 Jun 25;167(12):1312-20
pubmed: 17592106
Arch Intern Med. 2009 Dec 14;169(22):2142-7
pubmed: 20008700
Lancet Psychiatry. 2015 Nov;2(11):1002-12
pubmed: 26544749
BMJ Open. 2017 Nov 13;7(11):e017521
pubmed: 29133321
Fatigue. 2017;5(4):215-230
pubmed: 30854252
Am J Transl Res. 2013;5(1):53-68
pubmed: 23390566
Med Hypotheses. 2020 Nov;144:110055
pubmed: 32758891
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Nat Rev Immunol. 2005 Mar;5(3):243-51
pubmed: 15738954
Epidemiology. 2019 Nov;30(6):911-917
pubmed: 31584893
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Mil Med. 2016 Nov;181(11):e1515-e1531
pubmed: 27849485
J Inflamm Res. 2018 Mar 22;11:111-121
pubmed: 29606885
Vaccine. 2015 Nov 17;33(46):6173-7
pubmed: 26475444
Basic Clin Neurosci. 2020 Mar-Apr;11(2):179-184
pubmed: 32855777
Emerg Infect Dis. 2005 Aug;11(8):1297-300
pubmed: 16102324
Psychol Assess. 2016 Nov;28(11):1379-1391
pubmed: 26653052
BMC Neurol. 2011 Mar 24;11:37
pubmed: 21435231
J Transl Med. 2020 Feb 24;18(1):100
pubmed: 32093722
Sports Med. 2001;31(3):167-94
pubmed: 11286355